Targeted protein degradation: expanding the toolbox

Proteolysis-targeting chimeras (PROTACs) and related molecules that induce targeted protein degradation by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect...

Full description

Bibliographic Details
Main Authors: Schapira, M, Calabrese, M, Bullock, A, Crews, C
Format: Journal article
Language:English
Published: Nature Research 2019
_version_ 1797075486239621120
author Schapira, M
Calabrese, M
Bullock, A
Crews, C
author_facet Schapira, M
Calabrese, M
Bullock, A
Crews, C
author_sort Schapira, M
collection OXFORD
description Proteolysis-targeting chimeras (PROTACs) and related molecules that induce targeted protein degradation by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets. However, the technology is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated. Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degradation, and expansion of knowledge in this area is a key opportunity. Here, we briefly discuss lessons learned about targeted protein degradation in chemical biology and drug discovery and systematically review the expression profile, domain architecture and chemical tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.
first_indexed 2024-03-06T23:50:56Z
format Journal article
id oxford-uuid:7291c51e-b058-4f99-87c6-3085ed467c2e
institution University of Oxford
language English
last_indexed 2024-03-06T23:50:56Z
publishDate 2019
publisher Nature Research
record_format dspace
spelling oxford-uuid:7291c51e-b058-4f99-87c6-3085ed467c2e2022-03-26T19:50:56ZTargeted protein degradation: expanding the toolboxJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7291c51e-b058-4f99-87c6-3085ed467c2eEnglishSymplectic Elements at OxfordNature Research2019Schapira, MCalabrese, MBullock, ACrews, CProteolysis-targeting chimeras (PROTACs) and related molecules that induce targeted protein degradation by the ubiquitin-proteasome system represent a new therapeutic modality and are the focus of great interest, owing to potential advantages over traditional occupancy-based inhibitors with respect to dosing, side effects, drug resistance and modulating 'undruggable' targets. However, the technology is still maturing, and the design elements for successful PROTAC-based drugs are currently being elucidated. Importantly, fewer than 10 of the more than 600 E3 ubiquitin ligases have so far been exploited for targeted protein degradation, and expansion of knowledge in this area is a key opportunity. Here, we briefly discuss lessons learned about targeted protein degradation in chemical biology and drug discovery and systematically review the expression profile, domain architecture and chemical tractability of human E3 ligases that could expand the toolbox for PROTAC discovery.
spellingShingle Schapira, M
Calabrese, M
Bullock, A
Crews, C
Targeted protein degradation: expanding the toolbox
title Targeted protein degradation: expanding the toolbox
title_full Targeted protein degradation: expanding the toolbox
title_fullStr Targeted protein degradation: expanding the toolbox
title_full_unstemmed Targeted protein degradation: expanding the toolbox
title_short Targeted protein degradation: expanding the toolbox
title_sort targeted protein degradation expanding the toolbox
work_keys_str_mv AT schapiram targetedproteindegradationexpandingthetoolbox
AT calabresem targetedproteindegradationexpandingthetoolbox
AT bullocka targetedproteindegradationexpandingthetoolbox
AT crewsc targetedproteindegradationexpandingthetoolbox